Literature DB >> 22564298

Transient tachypnea of the newborn: the treatment strategies.

Murat Yurdakok1, Eren Ozek.   

Abstract

Transient tachypnea of the newborn results from delayed clearance of lung fluid and is a common cause of admission of full term and late preterm infants to neonatal intensive care units. The condition is particularly common after elective cesarean section. Conventional treatment involves supplemental oxygen, withholding enteral feeds and administration of intravenous fluids and antibiotics. Rarely, infants require CPAP and mechanical ventilation. Occasionally some babies develop severe hypoxemia and may require high concentrations of oxygen. The most effective strategy for accelerating reabsorbtion of fetal lung fluid is exogenous glucocorticoids. Potential therapies for TTN must be based on an understanding of the physiology of normal fetal lung fluid clearence at bith. Furosemide, racemic epinephrine and inhaled β-agonists have been studied for possible benefit in TTN. The routine administration of these drugs can not be recommended unless additional data become available.

Entities:  

Mesh:

Year:  2012        PMID: 22564298     DOI: 10.2174/1381612811209023046

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  3 in total

1.  Characteristics of respiratory distress syndrome in infants of different gestational ages.

Authors:  Huiqing Sun; Falin Xu; Hong Xiong; Wenqing Kang; Qiongdan Bai; Yinghui Zhang; Chongchen Zhou; Fangli Zhuang; Xiaoyang Wang; Changlian Zhu
Journal:  Lung       Date:  2013-05-31       Impact factor: 2.584

2.  Different antibiotic strategies in transient tachypnea of the newborn: an ambispective cohort study.

Authors:  Jinhui Li; Jinlin Wu; Lizhong Du; Yong Hu; Xiaoyan Yang; Dezhi Mu; Bin Xia
Journal:  Eur J Pediatr       Date:  2015-04-02       Impact factor: 3.183

3.  The Relationship between Neonatal Transient Tachypnea and Maternal Disease in Newborns.

Authors:  Anahita Khabaz Tarahi; Ali Omidian
Journal:  Iran J Public Health       Date:  2020-09       Impact factor: 1.429

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.